DermBiont's mission is to become the world's leading precision dermatology company developing and commercializing targeted topical therapeutics that treat, cure, and prevent skin diseases. The company aims to impact the root causes of skin diseases through the development of first-in-class targeted therapeutics with well-defined mechanisms of action. The company's targeted topical therapeutics pipeline includes two lead assets: SM-020 for the treatment of seborrheic keratoses and SM-030 for the treatment of melasma and other hyperpigmentation disorders of the skin.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 10/24/23 | $35,200,000 | Series B |
Civilization Ventures Double Point Ventures  Olive Tree Capital Viking Global Investors | undisclosed |
